Kennedy Capital Management, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

Kennedy Capital Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.83 - $16.49 $129,721 - $197,517	11,978 New	11,978 $188,000
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $82,014 - $118,195	4,178 Added 2.74%	156,475 $3.14 Million
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $1.67 Million - $2.89 Million	-96,143 Reduced 38.7%	152,297 $4.3 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $223,264 - $344,995	13,833 Added 5.9%	248,440 $4.27 Million
Q4 2022 Feb 14, 2023	SELL	$18.07 - $25.6 $151,715 - $214,937	-8,396 Reduced 3.46%	234,607 $4.72 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $2.46 Million - $3.85 Million	121,408 Added 99.85%	243,003 $5.26 Million
Q2 2022 Aug 10, 2022	BUY	$17.91 - $52.25 $2.18 Million - $6.35 Million	121,595 New	121,595 $3.42 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.